This controlled cross-sectional study examined hepatic steatosis and liver stiffness in patients with gout compared to metabolically stringent controls. The study, conducted from April 2024 to January 2026, involved 201 patients with gout and 80 controls without hypertension, diabetes mellitus, chronic kidney disease, or coronary artery disease.
Key Clinical Findings
Patients with gout demonstrated significantly higher controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) values. Unadjusted analyses revealed a higher odds of hepatic steatosis and increased liver stiffness in the gout group. Multivariable analysis indicated that BMI and alanine aminotransferase (ALT) were principal determinants of CAP, while BMI and age independently predicted continuous LSM.
Study Conclusions
Gout status was not independently associated with CAP, continuous LSM, hepatic steatosis, or increased liver stiffness after adjustment for age, BMI, and cardiometabolic covariates. The study suggests that non-invasive liver assessment in gout should be guided by cardiometabolic risk profile rather than the diagnosis of gout itself.